Not yet recruitingPhase 4NCT07013838

The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis

Studying Takayasu arteritis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chinese SLE Treatment And Research Group
Principal Investigator
Xinping Tian, MD
Peking Unione Mdecial College Hospital
Intervention
Deucravacitinib(drug)
Enrollment
50 enrolled
Eligibility
18 years · All sexes
Timeline
20252028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07013838 on ClinicalTrials.gov

Other trials for Takayasu arteritis

Additional recruiting or active studies for the same condition.

See all trials for Takayasu arteritis

← Back to all trials